Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. - Wikidata - awgldk - TriplyDB

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

http://www.wikidata.org/entity/Q39570902

about

Modulation of the cancer cell transcriptome by culture media formulations and cell density Profile of nintedanib in the treatment of solid tumors: the evidence to date RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer Genome-Wide Transcriptome and Binding Sites Analyses Identify Early FOX Expressions for Enhancing Cardiomyogenesis Efficiency of hESC Cultures.Pericytes, an overlooked player in vascular pathobiology Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment Metabolic control of cancer cell stemness: Lessons from iPS cells Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Screening assay for blood vessel maturation inhibitors.A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer The nutritional phenome of EMT-induced cancer stem-like cells Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.The PCa Tumor Microenvironment.Modeling community-wide molecular networks of multicellular systems Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets.Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts.Antiangiogenic therapies for advanced hepatocellular carcinoma.Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer Mechanisms that influence tumour response to VEGF-pathway inhibitors.SiRNA targeting EGFR effectively prevents posterior capsular opacification after cataract surgery.Angiogenesis in cancer: Anti-VEGF escape mechanisms Targeting angiogenesis in lung cancer - Pitfalls in drug development.Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines.A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.

P2860

Q24273332-9EF416B2-8F04-45A8-8A84-C41EA9C16857 Q26775134-17A82460-CDFB-4621-A823-6C99041B4DB1 Q27315803-59A5EEED-A7A5-4FD0-BC7C-837F8540286B Q27315948-94717C64-C4EB-4A12-90A8-078F4427514F Q27319765-2A7C76DB-DBA8-47F2-9423-9F684A4ED764 Q28070053-E7358B4C-54CA-423E-93B9-A900929267DB Q28081431-9F68A20F-F966-485A-A3C0-37E3878AF3E4 Q28081608-C363843D-7174-4244-9490-D9A5C0B7908B Q28732327-A935932E-E1FA-49CE-AE4A-23AE277C1DDB Q30544833-31C503CB-BFC9-4C50-8F76-4F64C536BECC Q33356339-8A3387D7-54B3-49A9-A811-1699010F7C67 Q33770680-ED885A5E-B1E4-4EBB-B6FA-2FDDA71BCD5D Q33862377-487DBA71-20FF-48D4-B9AC-B2F0E315671F Q33877489-5972B37A-A527-40B6-9476-2B2B4C3A034A Q33926952-99133967-2D88-4128-B23C-D3A8966DF538 Q34080323-F0F6622D-7203-4747-BEAE-D518EB57FBFA Q34100815-A5922AC2-6D3F-4EA0-8BE0-35DE4737267D Q35205410-C22CF2DE-04E8-4D8F-A2D5-DE2E1D1575D8 Q35217801-D6DEC3F4-D3F3-4F35-BC04-1CA06C295CCF Q35247504-9057DB44-B16A-46E3-900C-8785E03C3836 Q35536088-F8788AC1-361B-486F-9F0B-A5664DE7E5CC Q35603143-AC790981-4020-4CB6-BBE6-70F566008FF7 Q35917642-5D8DAC2E-3F5C-40EC-9B1C-F478362AC5C2 Q36392523-4554FC31-2D7A-4933-BA50-EE950822F39E Q36424741-4AE96E9C-CDB8-4B66-B157-BEF82B73E395 Q36486683-8F28AB4A-3839-4F5F-AC45-24BE7CB141C0 Q36804518-33D04C2A-EF83-4337-9B95-1EA162C411EB Q36828050-A25F0652-E118-46D3-95A9-5EDA0F9D3F24 Q36840372-055ED3CE-2298-4D5C-8712-0734EF84787B Q36856644-87FB0BFB-ED86-490D-8ADD-AB0413E466C8 Q37438981-AD93E204-81F2-4C77-A27F-3779776DE554 Q37640001-B500B3D2-996E-413C-86BE-80CF156BF406 Q38011768-F29EE590-46D2-40A8-B6A5-C2F883FD0C92 Q38125964-5F71BCB7-3CC6-443F-8787-88676D399887 Q38268452-CE9D7D00-4CF9-4E51-A790-844F5B628FFC Q38379731-55D6B9E1-8B90-4327-897E-6FB512D5CA74 Q38389975-C612DD9C-AA4A-4897-A166-81057A92F2C7 Q38389997-D29D3A83-369C-4C75-8BD9-6A94D71438D0 Q38885876-73CBE877-F1CD-4C4B-B877-BF2204F0F2AE Q39473604-399906E7-70E6-4857-A6EE-4724A3696F16

P2860

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

http://www.wikidata.org/entity/Q39570902

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@en

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@nl

type

label

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@en

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@nl

prefLabel

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@en

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@nl

P1433

Q39570902-55BDF1DB-4E34-46B3-B93F-6F33EFF0179A

P1476

Q39570902-1FA42A16-7E9C-4F2C-98AA-F8FB3DCCA04C

P2093

Q39570902-087CF9A9-E20D-4341-AEA6-1EBF03033587

Q39570902-26692D6D-330A-4878-89D1-C5FA0315810C

Q39570902-3960677A-2745-424C-9324-999C1AE3537F

Q39570902-568071C2-6256-4AE6-A39E-02632D63BBB5

Q39570902-614F9F40-E140-45B9-A68E-6C4FD6D32202

Q39570902-92EEFD81-1E98-42B0-8AED-54EAB1E269F5

Q39570902-AE801732-134E-4BEB-9311-98BFA726517A

Q39570902-C2C58772-FA57-47CE-85EC-CD37B32CEEA4

Q39570902-CFEB6E66-A440-4556-8472-898329F6DA31

Q39570902-DF9301A9-5877-4D14-8F99-4FA0F2583DE7

P2860

Q39570902-01222422-6A0A-4E11-965B-3E5C0E5F9BF1

Q39570902-07A109C0-7CE1-49AE-BE86-4E19F602F0E0

Q39570902-09B5EF79-593A-4678-B7DC-F6AE06C2811B

Q39570902-0D171228-3B97-4C4A-9A3D-1EFD7FB0781C

Q39570902-0EEDF115-2596-4586-9B2D-4A5D7D18C3ED

Q39570902-127F8C70-4680-4CC1-839C-D6B8E962539A

Q39570902-12A4A5A2-3DD7-447F-A88E-3A6D3049ACC6

Q39570902-13033745-5F88-4E2B-A2AE-042613468175

Q39570902-15FAD21C-2A61-43F6-9074-D10AA95B3BB7

Q39570902-167F0007-9624-431B-B6BC-E5CF4F4F3CFE

P304

Q39570902-A578D6D3-80FB-4D4F-A2BE-13A5B6F9E71D

P31

Q39570902-A77CFB3C-81C3-42F8-9590-517FC14C9A9A

P356

Q39570902-AA0E443A-F357-4572-AFBC-73D00450D907

P407

Q39570902-EAD77681-CB46-44D1-9A30-669082876D9D

P433

Q39570902-8008511B-836C-4C62-90AA-979659F09AA1

P478

Q39570902-96F780BB-6B6C-4605-91A1-775DD8F54C6D

P50

Q39570902-13E219B2-93F3-4C91-83AB-DA277F2CA440

Q39570902-783E1B81-B9E9-453E-AFAF-1C9C90CDB197

Q39570902-9C19833E-BFC2-42C5-8082-73A3D133F0F2

P577

Q39570902-38151B27-7E9B-4DB2-B6E3-EB2C919AC0C3

P698

Q39570902-03CBB803-60A4-4E82-8EC6-C8E084CDC9D2

P921

Q39570902-16972E8A-0931-4560-8517-E3BCEDB9F9B9

Q39570902-829A6BDF-913B-4DB2-87FD-9712B590B93E

P932

Q39570902-74CA01B3-683C-456A-B482-218B6EE527D3

P356

P1433

Journal of Clinical Investigation

P1476

Upregulated stromal EGFR and v ...... ant human lung adenocarcinoma.

@en

P2093

Baruch Erez

http://www.w3.org/2001/XMLSchema#string

Carol J Oborn

http://www.w3.org/2001/XMLSchema#string

Heather Y Lin

http://www.w3.org/2001/XMLSchema#string

Humam Kadara

http://www.w3.org/2001/XMLSchema#string

Ju-Seog Lee

http://www.w3.org/2001/XMLSchema#string

Jörg J Jacoby

http://www.w3.org/2001/XMLSchema#string

Li Xu

http://www.w3.org/2001/XMLSchema#string

Matthew H Herynk

http://www.w3.org/2001/XMLSchema#string

Monique B Nilsson

http://www.w3.org/2001/XMLSchema#string

Robert R Langley

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Modes of resistance to anti-angiogenic therapy

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Targeting HIF-1 for cancer therapy

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

P304

1313-1328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI42405

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

Fortunato Ciardiello

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21436589

http://www.w3.org/2001/XMLSchema#string

P921

P932

3070607

http://www.w3.org/2001/XMLSchema#string